Why KIMMTRAK showed OS benefit despite low ORR

November 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The Chain, host Rakesh Dixit speaks with Jallal on the potential advantages of bispecific T-cell engager therapy versus T-cell receptor therapy, biggest anticipated changes in drug discovery and development in the next 10 years, and how AI is going to impact the next generation of scientists. Plus, Jallal shares her experiences as the previous president of MedImmune and at AstraZeneca, what her most rewarding project was, and the transformations and achievements that occurred under her leadership. 

Links from this episode:  
Immunocore